Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a

Benjamin J. Shields,1,2 Jacob T. Jackson,1 Donald Metcalf,1,2 Wei Shi,3,4 Qiutong Huang,1 Alexandra L. Garnham,3 Stefan P. Glaser,1,2 Dominik Beck,5 John E. Pimanda,5 Clifford W. Bogue,6 Gordon K. Smyth,2,7 Warren S. Alexander,1,2 and Matthew P. McCormack1,2

1Cancer and Haematology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; 2Department of Medical Biology, University of Melbourne, Parkville, Victoria 3050, Australia; 3Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia; 4Computing and Information Systems, University of Melbourne, Parkville, Victoria 3050, Australia; 5Lowy Cancer Research Centre and the Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales 2052, Australia; 6Yale University School of Medicine, New Haven, Connecticut 06510, USA; 7Mathematics and Statistics, University of Melbourne, Parkville, Victoria 3050, Australia

Unlike clustered HOX genes, the role of nonclustered homeobox gene family members in hematopoiesis and leukemogenesis has not been extensively studied. Here we found that the hematopoietically expressed homeobox gene Hhex is overexpressed in acute myeloid leukemia (AML) and is essential for the initiation and propagation of MLL-ENL-induced AML but dispensable for normal myelopoiesis, indicating a specific requirement for Hhex for leukemic growth. Loss of Hhex leads to expression of the Cdkn2a-encoded tumor suppressors p16INK4a and p19ARF, which are required for growth arrest and myeloid differentiation following Hhex deletion. Mechanistically, we show that Hhex binds to the Cdkn2a locus and directly interacts with the Polycomb-repressive complex 2 (PRC2) to enable H3K27me3-mediated epigenetic repression. Thus, Hhex is a potential therapeutic target that is specifically required for AML stem cells to repress tumor suppressor pathways and enable continued self-renewal.

[Keywords: acute myeloid leukemia; transcription factor; self-renewal; homeobox; tumor suppressor]

Supplemental material is available for this article.

Received July 8, 2015; revised version accepted November 23, 2015.

In the hematopoietic system, self-renewal capacity is normally restricted to hematopoietic stem cells (HSC) and must be tightly controlled, since aberrant self-renewal is a hallmark of cancer [He et al. 2009]. Indeed, a number of leukemia oncogenes act via inducing self-renewal of either HSCs or more mature progenitors that have normally lost this property. Prototypical examples of this are oncogenic fusion proteins generated by chromosomal translocations at the MLL locus, which occur in ~5%–6% of acute myeloid leukemia [AML] cases, resulting in reciprocal chromosomal translocations that link MLL to a vast number of fusion partners [Krivtsov and Armstrong 2007]. The resultant fusion proteins activate target genes, including those in the HOXA cluster [HOXA5–10] and their essential cofactor, MEIS1, leading to expression of a “HOX code” that has been implicated in leukemia maintenance [Ayton and Cleary 2003; Horton et al. 2005]. In addition to this self-renewal network, recent studies have shown that sustained leukaemogenesis by MLL fusion oncogenes requires expression of epigenetic modifiers, including the Polycomb-repressive complex 2 [PRC2] [Neff et al. 2012; Tanaka et al. 2012; Shi et al. 2013]. PRC2 is composed of core components, including Suz12 and Eed along with the methyltransferases Ezh1 or Ezh2, which mediate silencing of key target genes via catalysis of the repressive mark H3K27me3 [Margueron and Reinberg 2011].

The above studies have identified important roles for clustered HOX family [class I] homeobox genes in regulation of both normal HSCs and leukemic stem cells [LSCs] [Argiropoulos and Humphries 2007; Alharbi et al. 2013]. However, the role of HOX genes in MLL-associated leukemia is complicated by the fact that MLL fusion proteins activate many HOX cluster genes, and these exhibit
partial redundancies in leukemia maintenance [Kumar et al. 2004; So et al. 2004]. Recently, evidence has emerged that nonclustered (class II) homeobox genes may also play important roles in MLL-driven leukemia. These include members of the caudal-type homeobox (CDX) subfamily of ParaHox genes that are overexpressed in AML and act upstream of HOX genes to promote their expression [Bansal et al. 2006; Scholl et al. 2007; Rawat et al. 2012]. In addition, the H2O-like homeobox (HLX) gene is overexpressed in most AML cases and promotes leukemogenesis [Kawahara et al. 2012]. Together, these studies indicate an important role for both clustered and nonclustered homeobox genes in the initiation and maintenance of AML.

The hematopoietically expressed homeobox gene (Hhex, also known as Prh), encodes a member of the NK-like (NKL) subclass of homeodomain proteins that is thought to function primarily as a transcriptional repressor [Guiral et al. 2001; Swingler et al. 2004; Souli and Jayaraman 2008]. It was first identified via its expression in hematopoietic tissues, being abundantly expressed in HSCs and progenitors before being down-regulated upon differentiation [Crompton et al. 1992; Bedford et al. 1993]. In the T-cell lineage, down-regulation of Hhex is crucial, as overexpression causes thymocyte self-renewal and T-cell leukemia in mouse models and is associated with early T-cell precursor ALL (ETP-ALL) in humans [George et al. 2003; McCormack et al. 2010, 2013]. Furthermore, a rare chromosomal translocation t[10;11] (q23;p15) results in the generation of a NUP98-HHEX fusion oncogene in AML [Jankovic et al. 2008].

Loss of Hhex during embryonic development is lethal due to a failure of liver development, precluding the analysis of hematopoietic development in knockout mice [Keng et al. 2000; Martinez Barbera et al. 2000]. However, studies using embryoid body differentiation and blastocyst complementation approaches have defined critical roles for Hhex in the development of definitive HSCs and B cells [Bogue et al. 2003; Guo et al. 2003; Kubo et al. 2005; Paz et al. 2010].

Using Hhex conditional knockout mice [Hunter et al. 2007], we showed recently that Hhex is dispensable for maintenance of adult HSCs and myeloid lineages but essential for the commitment of diverse lymphoid lineages at the stage of the common lymphoid progenitor (CLP) [Jackson et al. 2015]. Moreover, Hhex is required for the radioresistance of LSCs in a mouse model of human ETP-ALL [Shields et al. 2015]. However, the role of Hhex in myeloid leukemia has not been studied previously. Here we show that Hhex is overexpressed in human AML and is essential for myeloid leukemia driven by the oncogenic fusion protein MLL-ENL as well as its downstream effectors, HoxA9 and Meis1, while being dispensable for normal myelopoiesis. Conditional deletion of Hhex results in loss of PRC2-mediated epigenetic silencing of the Cdkn2a locus, resulting in induction of the Cdkn2a-encoded tumor suppressors p16INK4a and p19ARF. Therefore, targeting Hhex is a potential strategy to induce tumor suppression to specifically inhibit myeloid leukemia.

Results

Hhex is overexpressed in human AML and required for initiation of AML by MLL-ENL

As Hhex regulates the development of definitive HSCs and is highly expressed in human ETP-ALL, we assessed whether its expression is altered in AML patient samples. Using a curated microarray database [HemaExplorer] [Bagger et al. 2013], we found that Hhex is highly expressed in early progenitors before being down-regulated in all lineages except monocytes and B cells [Fig. 1A]. Strikingly, expression was twofold to fourfold higher in AML patient samples relative to normal HSCs, irrespective of leukemia subtype, with highest expression found in AML with inv[16]/t[16,16] or t[8;21] translocations [Fig. 1A]. Analysis of an independent patient cohort (n = 536) [Verhaak et al. 2009] confirmed high HHEX expression in AMLs with the favorable inv[16]/t[16,16] and t[8;21] karyotypes [Fig. 1B]. Consistent with the above observation, HHEX expression was highest in the favorable risk group [Fig. 1C]. Patients in this cohort were also assigned into prognostic groups using the European Leukemia Network (ELN) classification [Li et al. 2013]. Patients within the intermediate risk groups could be dichotomized into those with better or worse outcomes based on an automatically determined [k-means clustering] [Difner et al. 2013] HHEX expression threshold [Fig. 1D,E]. Five-year survival rates were ∼25% versus ∼50% [Int-1; P = 0.01] and ∼30% versus ∼50% [Int-2; P = 0.05] in high and low HHEX expressors, respectively. These data show that HHEX expression in human AML is context-dependent and adds value to existing prognostic classification systems.

We next sought to determine whether Hhex is required for the development of myeloid leukemia by the MLL-ENL fusion oncogene. As AML induced by MLL fusion oncogenes is initiated from HSCs and myeloid progenitors up to and including granulocyte/monocyte progenitors [GMPs] [Cozzio et al. 2003; Kvitvostov et al. 2006], we first tested whether Hhex loss had any effect on the number and function of these cells following Hhex deletion in the bone marrow (BM) of Hhex+/ΔMx mice. Flow cytometric analysis revealed no defects, with a slightly increased frequency of long-term HSCs (LT-HSCs), common myeloid progenitors (CMPs), and myeloid-erythroid progenitors (MEPs) in Hhex+/ΔMx mice when compared with Hhex+/+ controls [Supplemental Fig. S1A–C]. We next tested the function of myeloid progenitors in Hhex+/ΔMx mice in semisolid agar colony assays. When cultured in a mixture of cytokines (IL-3, stem cell factor [SCF], and EPO), BM from Hhex+/ΔMx mice showed no defect in colony formation, with slightly increased frequencies of granulocyte and macrophage colonies [Supplemental Table S1]. Culture in individual cytokines revealed additional differences, with increased numbers of granulocyte colonies in the presence of GM-CSF or IL-3 and a reduction in macrophage colonies in response to GM-CSF or M-CSF [Supplemental Table S1]. Overall, these data indicate that Hhex is dispensable for the development and function of myeloid progenitors in vitro and in vivo.
To assess whether Hhex is required for initiation of AML, lineage-depleted BM cells from Hhex^−/ΔMx^ mice were transduced with MSCV-IRES-GFP retroviruses expressing MLL-ENL and injected into irradiated congenic (Ly5.1) recipient mice (Fig. 2A). At the time of injection, Hhex^−/ΔMx^ BM cells showed levels of viral infection comparable with control (Hhex^+/fl^) BM cells (Supplemental Fig. S2A). Notably, MLL-ENL expression in Hhex^+/fl^ BM led to a significant increase in Hhex mRNA expression compared with transduction with control [MIG] retrovirus (Fig. 2B).

All recipient mice, regardless of the genotype of donor cells, showed complete myeloid repopulation in the peripheral blood 4 wk after transplantation (Fig. 2C). Donor-derived lymphoid cells were reduced in recipients reconstituted with Hhex^−/ΔMx^ BM [data not shown], consistent with our previous report that Hhex is required for lymphoid development downstream from the CLP but is dispensable for normal adult HSC function in transplant assays [Jackson et al. 2015]. The levels of transduction with control [MIG] retrovirus was similar in

**Figure 1.** Hhex is overexpressed in human AML and is associated with an adverse outcome in ELN intermediate-1 and intermediate-2 classified AML. (A) Expression of Hhex expression in four AML karyotypes, hematopoietic progenitors, and differentiated cells using the HemaExplorer microarray database. Single points on the graph represent the average HHEX expression of two individual microarray probes for the cell types indicated. [*] \( P < 0.05; [**] P < 0.001, \) Student’s t-test. \( [\beta] \) HHEX expression levels (Robust Multiarray Average [RMA] normalized; log_2) in AML patients from the HOVON (Hemato-Oncologie voor Volwassenen Nederland) cohort with frequent cytogenetic abnormalities. [NN] Cytogenetically normal AML. (C) HHEX expression levels (RMA normalized; log_2) in patients from the HOVON cohort stratified according to ELN classes [Li et al. 2013]. (D) Five-year overall survival of patients classified as ELN intermediate-1 with high/low expression [k-means clustering] of HHEX. \( [\beta] \) Five-year overall survival of patients classified as ELN intermediate-2 with high/low expression [k-means clustering] of HHEX. In D and E, \( P \) was determined using a log rank (Mantel-Cox) test.

**Figure 2.** Hhex^−/ΔMx^ or Hhex^+/fl^ BM [Fig. 2D]. Transduction with MLL-ENL retrovirus was initially low in both Hhex^−/ΔMx^ and Hhex^+/fl^ BM cells; however, transduced control [Hhex^+/fl^] BM cells were rapidly expanded both in vitro [Supplemental Fig. S2B] and in vivo, with the peripheral blood of recipient mice containing abundant donor-derived Mac1^+^GFP^+^ cells (Fig. 2E). In striking contrast, donor-derived Mac1^+^GFP^+^ cells were almost completely absent in the peripheral blood of Hhex^−/ΔMx^-AML MLL-ENL recipient mice at 4 wk after transplant and continued to decline by 8 wk after transplant (Fig. 2D,E). Accordingly, while all Hhex^+/fl^ MLL-ENL recipients succumbed to myeloid leukemia within 11 wk, none of the eight Hhex^−/ΔMx^ MLL-ENL recipients developed leukemia within a 4-mo observation period (Fig. 2F). Thus, while Hhex is dispensable for adult HSC function and myeloid reconstitution, it is essential for the initiation of AML by MLL-ENL.
Hhex is required for maintenance of AML induced by MLL-ENL

To determine whether Hhex is required for maintenance of AML by MLL-ENL, we generated ROSA26-CreERT2; Hhex−/− mice [hereafter termed CreERT2;Hhex−/− mice], in which deletion of the Hhexβ allele can be induced by tamoxifen-regulated Cre recombinase [hereafter termed HhexΔERT2] (Fig. 3A). BM from these mice was used to generate MLL-ENL-induced myeloid leukemias, as above. Next, 10,000 flow cytometry-sorted leukemia-initiating cells (LICs; GFP+, Mac1+, Kit+) from primary leukemic mice were injected into secondary recipients, and the Hhexβ allele was deleted by two tamoxifen administrations starting at 10 d after transplant [Fig. 3A]. Development of fatal leukemia in placebo-treated controls occurred rapidly, within 23 d after transplant [Fig. 3B]. Tamoxifen administration led to a small delay in the development of control Hhex+/β tumors, likely due to Cre-mediated toxicity. In contrast, survival of tamoxifen-treated Hhex+/β tumor recipients was more than doubled relative to placebo-treated controls [Fig. 3B]. Strikingly, genomic PCR analysis revealed that while the Hhexβ allele was completely deleted in relapsed MLL-ENL Hhex−/ΔERT2 leukemias, secondary leukemias developing in recipients of MLL-ENL Hhex−/ΔERT2 LICs were completely nondeleted at the Hhexβ locus (Fig. 3C). Thus, secondary leukemias emanated from a small fraction of Hhexβ [nondeleted] cells that remained after tamoxifen treatment. To verify that Hhexβ deletion is not toxic to normal myeloid cells, mice were reconstituted with BM from CreERT2;Hhex−/− mice, and, 1 mo later, the Hhexβ allele was deleted by tamoxifen treatment. We saw no selection for nondeleted Hhexβ in myeloid cells in the peripheral blood or BM of these chimeric mice up to 4 mo after tamoxifen treatment [Fig. 3D]. Thus, Hhex is dispensable for normal myelopoiesis but critical for establishment and maintenance of MLL-ENL-induced myeloid leukemia.

Next, we assessed the impact of Hhex deletion in the whole animal by administering tamoxifen to CreERT2; Hhex−/− mice. These mice were closely monitored for 1 mo, during which time no physical signs of illness were evident. Furthermore, no significant pathology was observed in Hhex-null animals [Supplemental Fig. S3], and genomic PCR analysis of various tissues and organs demonstrated recombination of the Hhexβ allele in all tissues (Fig. 3E). Thus, systemic loss of Hhex in adult mice has minimal short-term side effects, further demonstrating the potential for Hhex as a therapeutic target in AML.

To determine the cellular effects of Hhex deletion on MLL-ENL-induced leukaemic cells, we established cell
HoxA/Meis1 genes to maintain the self-renewal capacity of MLL-ENL-induced leukemias. To test this directly, BM cells from Hhex−/ΔMx mice were transduced with MSCV-HoxA9-Meis1 retroviruses as above and injected into irradiated recipient mice. All control [Hhex−/−] HoxA9-Meis1 recipient mice succumbed to leukemia within 9 wk; however, leukemia development in Hhex−/ΔMx HoxA9-Meis1 recipients was significantly delayed [Supplemental Fig. S5A]. PCR analysis of the BM of Hhex−/ΔMx HoxA9-Meis1 leukemic mice revealed selection of undeleted HhexΔ leukemia cells [Supplemental Fig. S5B]. Thus, Hhex is also required for HoxA9/Meis1-driven AML, indicating that it acts independently of HoxA/Meis1 to maintain self-renewal of AML stem cells.

A comparison of differentially expressed genes between Hhex-deleted LICs and cell lines showed that genes up-
regulated in Hhex-deleted LICs were generally also up-regulated following Hhex deletion in cell lines (Fig. 5B). In contrast, genes down-regulated in Hhex-deleted LICs and cell lines showed only weak correlation [data not shown]. Of the genes up-regulated after Hhex deletion in both LICs and Hhex−/ΔMx cell lines, we noted the cell cycle inhibitors Cdkn2a and Cdkn2b [Fig. 5B,C]. As these genes encode potent cell cycle inhibitors, we hypothesized that they may be responsible for the growth arrest following Hhex deletion. Furthermore, analysis of LSK cells from Hhex−/ΔMx mice revealed that the levels of Cdkn2a and Cdkn2b expression induced in these cells were extremely small when compared with LICs and cell lines, which may explain why loss of Hhex causes specific loss of LICs while sparing normal HSCs (Fig. 5C).

We next performed immunoblotting experiments to test whether loss of Hhex results in induction of the Cdkn2a-encoded tumor suppressor proteins p16INK4a and p19ARF. This showed abundant expression of both p16INK4a and p19ARF in Hhex−/ΔERT2 MLL-ENL cell lines following tamoxifen treatment [Fig. 5D] that were induced with kinetics similar to the loss of cycling cells (S and G2/M phases) in Hhex-deleted cell lines (Fig. 5E). To determine whether the growth inhibitory effects of Hhex deletion in AML cell lines could be reversed by Hhex re-expression, we transduced pools of Hhex-null AML cells (4 d after tamoxifen treatment) with retroviruses bearing Hhex with a C-terminal Flag epitope tag (termed Hhex-F). Overexpression of Hhex-F in Hhex-null MLL-ENL cells was associated with significant toxicity [Supplemental Fig. S6A]. However, stable Hhex-F-rescued cell lines expressing physiological levels of Hhex were selected over time and used in subsequent assays. Hhex-F transduced cells displayed myeloid-specific marker expression profiles similar to Hhex-nondeleted AML cells [Supplemental Fig. S6B] and did not show the up-regulation of p16INK4a and p19ARF observed in Hhex-null AML lines [Fig. 5F]. Together, these data suggest that loss of Hhex may restrict growth of AML cells by causing the induction of tumor suppressor pathways.

Deletion of p16INK4a and p19ARF tumor suppressors restores AML growth in the absence of Hhex

To assess the role of tumor suppressor pathways in the growth arrest seen upon Hhex deletion in AML cells, we cloned lentiviral CRISPR vectors (pLentiCRISPR) [Shalem et al. 2014] with guide sequences against Cdkn2a, Cdkn2b, and p53 [Supplemental Table S5]. As Cdkn2a encodes both p16INK4a and p19ARF tumor suppressors, we designed guide sequences to target each alternative transcript-coding region independently through their unique first exons as well as together via their shared second exon. A guide sequence against firefly luciferase served as a control. These constructs were used to stably transduce CreERT2;Hhex−/ΔMx cell lines and Hhex−/ΔMx deleted by tamoxifen treatment. Immunoblotting analysis of Hhex-deleted cells showed a complete absence of p16INK4a and p19ARF upon CRISPR-Cas9-mediated deletion [Fig. 6A]. We next tested whether loss of these proteins was sufficient to restore growth of Hhex-deleted MLL-ENL cell lines. CRISPR-Cas9-mediated targeting of p15INK4b, encoded by Cdkn2b, did not rescue the growth of leukemia cells after Hhex deletion, with growth arrest occurring after 2 wk [Fig. 6B]. While deletion of p16INK4a caused a partial rescue of cell numbers following Hhex deletion, these cells still showed eventual growth arrest [Fig. 6B]. In contrast, deletion of p19ARF or combined deletion of both p16INK4a and p19ARF led to an almost complete rescue of cell growth upon Hhex deletion [Fig. 6B]. As p19ARF acts in part via the p53 pathway, we also designed guide sequences to target p53. This showed a partial rescue of growth in Hhex-deleted cells, which was less than that seen upon p19ARF deletion, suggesting that p19ARF functions largely independently of p53 in inhibiting AML growth. Furthermore, and consistent with the importance of Hhex-dependent suppression of p16INK4a and p19ARF for the maintenance of AML growth, Hhex−/ΔERT2 cells lacking p16INK4a and p19ARF continued to proliferate and maintained normal levels of myeloid-
AML in vivo, we generated Cre<sup>ERT2</sup>;Hhex<sup>−/−</sup> of Hhex<sup>fl/fl</sup> in Hhex-deleted, plant (Fig. 6C). Furthermore, we saw no selection for undeleted Hhex<sup>−/−</sup> in the attenuation of MLL-ENL-induced leukemia developed from Hhex<sup>−/−</sup> by tamoxifen administration 7 d later. Strikingly, MLL-ENL-induced myeloid leukemia developed from Hhex<sup>−/−</sup> was used to generate MLL-ENL-induced myeloid leukemia, as above. Next, LICs from leukemic mice were compared with Hhex<sup>−/−</sup> in LICs lacking Cdkn2a induction of tumor suppressors encoded by HoxA and associated genes, as shown for wild-type LSK cells and compared with MLL-ENL LICs and cell lines with the indicated Hhex genotype. [B] GSEA showing the association between genes up-regulated following Hhex deletion in LICs and MLL-ENL-induced cell lines. Genes significantly up-regulated in Hhex-deleted LICs were compared in MLL-ENL-induced control (HET) and Hhex-deleted (knockout) cell lines. [Left] In the enrichment plot, skewing to the right indicates that most genes are also up-regulated in Hhex-deleted cell lines. [Right] The heat map shows the top 30 genes most up-regulated in Hhex-deleted cell lines. Cdkn2a and Cdkn2b are indicated by arrowheads. [C] Induction of Cdkn2a expression upon Hhex deletion. Tracks show RNA sequencing coverage of the indicated cell types and Hhex genotypes at the Cdkn2a locus. Units are reads per million mapped reads (RPM). [D,E] Kinetics of p16<sup>INK4a</sup> and p19<sup>ARF</sup> expression and cell cycle arrest in Hhex Het and knockout MLL-ENL cell lines following deletion of Hhex. Cells were harvested at the times indicated following tamoxifen treatment and either lysed in RIPA buffer and processed for immunoblotting with antibodies specific for p16<sup>INK4a</sup>, p19<sup>ARF</sup>, and HSP70 (D) or fixed, permeabilized, and stained with DAPI and Ki67-PE-Cy7 for cell cycle analysis by flow cytometry (E). [F] Retrotransduction of Hhex-null AML cells with Hhex-F suppresses induction of p16<sup>INK4a</sup> and p19<sup>ARF</sup>. Hhex Het, Hhex-deleted [knockout], and Hhex-rescued [KO+Hhex-F] cell lines were lysed in RIPA buffer and processed for immunoblotting with antibodies specific for Hhex and as in D.

Specific markers [Supplemental Fig. S7A] and blast cell morphology [Supplemental Fig. S7B]. Hence, growth arrest of AML cell lines following Hhex deletion is due to induction of tumor suppressors encoded by Cdkn2a.

To assess the role of Hhex-dependent suppression of Cdkn2a in the attenuation of MLL-ENL-induced AML in vivo, we generated Cre<sup>ERT2</sup>;Hhex<sup>−/−</sup> mice on the Cdkn2a knockout background. BM from these mice was used to generate MLL-ENL-induced myeloid leukemias, as above. Next, LICs from leukemic mice were injected into secondary recipients, and Hhex<sup>−/−</sup> was deleted by tamoxifen administration 7 d later. Strikingly, MLL-ENL-induced leukemia developed from Hhex<sup>−/−</sup> LICS lacking Cdkn2a, in contrast to Cdkn2a wild-type cells that never developed leukemia up to 4 mo after transplant [Fig. 6C]. Furthermore, we saw no selection for undeleted Hhex<sup>−/−</sup> in Hhex-deleted, Cdkn2a-null leukemias [Fig. 6D]. Thus, loss of Cdkn2a allows maintenance of AML in the absence of Hhex, indicating that the primary effect of Hhex in AML is to repress Cdkn2a.

Hhex represses p16<sup>INK4a</sup> and p19<sup>ARF</sup> expression via regulation of PRC2 function

Previous studies have indicated an important role for homeobox transcription factors, including Hoxa9 and Hlx1, in the recruitment of PRC2 to the Cdkn2a/b locus to facilitate transcriptional repression and the maintenance of self-renewal potential [Martin et al. 2013; Collins et al. 2014]. We therefore tested whether Hhex mediates repression of this locus in AML cells via PRC2-mediated epigenetic silencing using antibodies directed against the PRC2-encoded repressive mark H3K27me3 as well as the activating mark H3K4me3 for chromatin

84 GENES & DEVELOPMENT
immunoprecipitation (ChIP) sequencing. H3K27me3 marks were abundant in Hhex−/fl MLL-ENL cell lines both within the gene body of Cdkn2a (Fig. 7A; Supplemental Fig. S8A) and Cdkn2b (Fig. 7A) and at an enhancer ∼50 kb upstream that has been previously shown to be important for HoxA9-mediated repression of Cdkn2a (Fig. 7A; Collins et al. 2014). Conversely, the H3K27me3 mark was greatly reduced in Hhex-null MLL-ENL cells (Fig. 7A; Supplemental Fig. S8A), including the upstream enhancer region, with re-expression of Hhex-F rescuing the deposition of this mark (Fig. 7A; Supplemental Fig. S8A).

To determine whether Hhex binds to the Cdkn2a locus, we performed ChIP sequencing on Hhex-F transduced Hhex−/ΔERT2 cells [Supplemental Fig. S8A] using an antibody against the Flag epitope. This revealed a peak overlapping a bivalently marked region encompassing Exon1α [Supplemental Fig. S8B] that has been previously shown to be subject to antagonistic regulation by Polycomb and SWI/SNF complexes to modulate the expression of p16INK4a (Wilson et al. 2010). Subsequent ChIP-PCR experiments confirmed that this region is bivalently marked, with loss of Hhex causing a decrease in repressive marks and a reciprocal increase in active marks (Supplemental Fig. S8C), and that Hhex binds directly (Supplemental Fig. S8D).

To establish whether Hhex regulates PRC2-repressed target genes globally, we performed GSEA of our RNA sequencing data from MLL-ENL cell lines using gene sets from two separate studies that have described critical PRC2 targets in MLL-AF9-induced leukemia (Supplemental Table S6; Shi et al. 2013; Xu et al. 2015). We found that, in both cases, loss of Hhex caused significant reactivation of PRC2 targets, including five genes (Cdkn2b, Zmat3, Igf1, Ryk, and Serpine2) that are in common between the...
two gene sets (Supplemental Fig. S9). Thus, Hhex regulates a subset of PRC2 target genes in addition to Cdkn2a.

Next, to determine whether Hhex affects the PRC2-encoded epigenetic mark H3K27me3 globally, we analyzed this mark in Hhex-null cell lines. Remarkably, we found that loss of Hhex caused a significant change in the deposition of H3K27me3 at only nine separate gene-coding loci containing 13 genes (Fig. 7B). Two genes demonstrated significantly increased H3K27me3 deposition, and 11 genes, including Cdkn2b, showed significantly decreased H3K27me3 deposition (Fig. 7B). All of these genes showed a strong inverse correlation between H3K27me3 marking and RNA expression, confirming them as bona fide Hhex-dependent PRC2 target genes (Fig. 7C). Re-expression of Hhex [Hhex-F] restored the H3K27me3 status of all 13 genes but also resulted in significant changes in the H3K27me3 status of previously unregulated genes, suggesting that Hhex can cause aberrant epigenetic regulation when ectopically expressed (Fig. 7D). However, loss of Hhex did not alter the overall level of H3K27me3, as assessed by Western blotting [Fig. 7E], indicating that Hhex is not required for PRC2 function generally but regulates its function at specific loci that are required for leukemic growth.

To determine whether Hhex interacts with the PRC2 complex, we performed coimmunoprecipitation assays using Flag-tagged Hhex [Hhex-F]. This showed that Hhex coprecipitates with the PRC2 core component Suz12 [Fig. 7F]. Furthermore, using Suz12 ChIP quantitative PCR analysis, we observed Hhex-dependent enrichment of Suz12 at the H3K27me3 peak identified above [Supplemental Fig. S8E]. However, the observation that only a small proportion of Suz12 was bound to Hhex may explain why loss of Hhex does not affect PRC2 function globally. Together, these data suggest a model in which Hhex mediates the recruitment of PRC2 to key loci, including Cdkn2a to facilitate epigenetic repression and enable continued cycling of LSCs in AML [Fig. 7G].

Discussion
As Hhex is a critical regulator of HSC development during embryogenesis that is overexpressed in human AML, we

Figure 7. Hhex is required for the repressive function of PRC2 at the Cdkn2a/b locus. (A) ChIP sequencing analysis showing enrichment of H3K27me3 (red) and H3K4me3 (green) across a broad region of chromosome 4 encompassing Cdkn2a and Cdkn2b in the indicated cell lines. Units are reads per million mapped reads (RPM). (B) The mean difference plot of H3K27me3 (gene body) in MLL-ENL-induced control (−/−) and Hhex-deleted (−/−ΔERT2) cell lines demonstrates that Hhex regulates a discrete set of genes. Blue dots represent genes with significantly decreased H3K27me3, and red dots represent genes with significantly increased H3K27me3 following Hhex deletion. Dotted lines indicate genes that are located at the same loci. (C) Correlation analysis of differentially methylated genes identified in B that also have significant changes (greater than two log fold change) in mRNA expression level between MLL-ENL-induced control (−/−) and Hhex-deleted (−/−ΔERT2) cell lines identified by RNA sequencing, P = 0.0002. (D) Mean difference plot of H3K27me3 (gene body) in Hhex-deleted (−/−ΔERT2) cell lines and Hhex-F-rescued −/−ΔERT2 cell lines. Differentially methylated genes identified in B are highlighted with green dots. (E) Immunoblotting of whole-cell lysates from control (−/−) and Hhex-deleted (−/−ΔERT2) and Hhex-F-rescued (−/−ΔERT2 +Hhex-F) cell lines. (F) Coimmunoprecipitation of Hhex-F and PRC2 component suz12 in −/−ΔERT2 +Hhex-F cell lines. [in] Input (1/50th immunoprecipitation); [IP] M2-Flag immunoprecipitate. (G) Model of Hhex-dependent regulation of Cdkn2a by recruitment of PRC2.
assessed the requirement for this factor in MLL-ENL-induced myeloid leukemia using a conditional knockout model. We found that Hhex is required to initiate MLL-ENL-driven AML and that deletion of Hhex in established leukemia invariably leads to selection for nondeleted clones, indicating that Hhex is essential for development and sustained growth of leukemia. Transcriptome analysis showed that MLL-ENL-induced HoxA overexpression was not affected by Hhex deletion, indicating that Hhex is required independently of the MLL-induced "Hox code" to maintain leukemogenesis. Accordingly, leukemogenesis by collaborating HoxA9 and Meis1 also required Hhex. Together, these results indicate that Hhex acts independently of HoxA/Meis1 genes, which are established drivers of MLL fusion leukemia in this setting (Krivtsov et al. 2006).

By transcriptome analysis, we found that loss of Hhex causes up-regulation of cell cycle inhibitors encoded by CDkn2a and CDkn2b in MLL-ENL transformed LICs and cell lines. Remarkably, loss of CDkn2a, which encodes both p16\textsuperscript{INK4a} and p19\textsuperscript{ARF}, restored the growth of MLL-ENL-induced AML both in vitro and in vivo, with individual targeting indicating that p19\textsuperscript{ARF} is the major mediator of growth arrest following Hhex deletion. As p53 gene disruption only partially rescued growth of AML cells when Hhex was deleted, our data also suggest that the cell cycle inhibitory action of p19\textsuperscript{ARF} is largely independent of its canonical ability to inhibit MDM2 and stabilize p53. Indeed, several p53-independent p19\textsuperscript{ARF} functions have been reported, including sequestration of Myc and E2F1 and attenuation of ribosomal RNA transcription and processing (Sherr 2006; Lessard et al. 2010).

In HSCs and AML stem cells, suppression of CDkn2a and CDkn2b is facilitated by Polycomb group (PCG) proteins contained within PRC1 and PRC2 (Lessard and Sauvageau 2003; Hidalgo et al. 2012; Tanaka et al. 2012). PRC2-dependent silencing of CDkn2a is critical for maintenance of self-renewal capacity, as loss of the core PRC2 component Eed or both of the PRC2 enzymatic components Ezh1 and Ezh2 leads to loss of AML stem cells (Neff et al. 2012; Tanaka et al. 2012; Shi et al. 2013). Furthermore, chemical inhibition of PRC2 function inhibits growth of leukemia driven by MLL fusion proteins (Kim et al. 2013; Xu et al. 2015). However, as PRC2 is also required for normal HSC function, the therapeutic potential of targeting this complex is presently unclear (Xie et al. 2014).

Homeobox transcription factors, including the Hhex-related Hlx1 protein and HOXA9, have recently been implicated in the recruitment of PCGs to the CDKN2A locus in human fibroblast cell lines, which prevents p16\textsuperscript{INK4a}-dependent cell cycle arrest (Martin et al. 2013). Our findings identify Hhex as a crucial homeobox protein that similarly enables PRC2 function at the CDkn2a locus to maintain the self-renewal capacity of MLL-ENL-induced AML. Hhex is also required for maintaining the H3K27me3 mark across an enhancer region ∼50 kb upstream of CDkn2b, which was shown to be essential for HoxA9/C/EBPα-dependent suppression of CDkn2a and CDkn2b in HoxA9;Meis1-driven AML (Collins et al. 2014). We found that the magnitude of induction of CDkn2a in AML cell lines and LICs following Hhex loss greatly exceeds that in normal LSK cells. This implies that Hhex-independent mechanisms maintain epigenetic silencing of CDkn2a in normal HSCs but not LICs, potentially explaining the specific requirement for Hhex in AML stem cells.

In AML patient blasts, CDkn2a/b is often repressed via H3K27me3 in combination with CDkn2b promoter methylation (Paul et al. 2010), and low expression of the CDkn2a-encoded tumor suppressors p16\textsuperscript{INK4a} and p14\textsuperscript{ARF} correlates with poor outcome (Müller-Tidow et al. 2004; de Jonge et al. 2009, Paul et al. 2009). However, as CDkn2a/b are rarely mutated in AML, targeting epigenetically silenced CDkn2a is an attractive therapeutic option (LaPak and Burd 2014). This study highlights inhibition of Hhex as a potential strategy to relieve PRC2-mediated epigenetic suppression of CDkn2a and specifically inhibit self-renewal of AML stem cells.

### Material and methods

#### Mice

All mice used were on a C57BL/6 background. The Hhex\textsuperscript{fl} [Hunter et al. 2007], Hhex\textsuperscript{-} [Bogue et al. 2003], Mx-Cre [Kuhn et al. 1995], ROSA26-Cre\textsuperscript{ERT2} [Seibler et al. 2003], and Ink4a/Arf\textsuperscript{-/-} [Serrano et al. 1996] mouse strains have been described. Four-week-old to 6-wk-old CD45.1\textsuperscript{+} C57BL/6 mice [Ly5.1; Walter and Eliza Hall Institute] were used as recipients in chimeric transplant experiments. To induce expression of the Mx1-Cre allele, polyinosinic–polycytidylid acid sodium salt [poly(I:C); Sigma] dissolved in saline was administered to mice [12 mg per kilogram of mouse body weight] intraperitoneally at 7 wk of age at least 3 wk prior to their use in experiments. To induce expression of the ROSA26-Cre\textsuperscript{ERT2} allele, mice were administered 70 μL of tamoxifen [4.2 mg [Sigma] in vehicle; 10% ethanol, 90% peanut oil [Sigma]] by oral gavage on two consecutive days, whereas placebo-treated mice received 70 μL of vehicle control. All experiments were approved by the Walter and Eliza Hall Institute Animal Ethics Committee.

#### Flow cytometry

Antibodies used in experiments for lineage marker depletion included rat anti-mouse B220 (RA3-6B2), CD3 (KT3-1-1), CD4 (GK1.5-7), CD8 [53.6.7], CD19 [ID3], Gr-1 (RB6-8C5), Mac-1 (M1/70), and TER119 (Ly76), all from the Walter and Eliza Hall Institute Monoclonal Antibody Facility. The exclusion of hematopoietic lineage cells from murine BM was performed using anti-rat antibodies in combination with sheep anti-rat IgG-coated immunomagnetic beads [Invitrogen]. Antibodies used for analysis and sorting by flow cytometry included goat anti-rat IgG-Alexa680 [Invitrogen, A21096] and the following rat anti-mouse biotinylated or fluorophore-conjugated antibodies purchased from either eBiosciences, Biolegend, BD Pharmingen, or Invitrogen or produced by the Walter and Eliza Hall Institute Monoclonal Antibody Facility.
B220 [RA3-6B2], c-Kit [ACK-2], CD4 [ GK1.5-7], CD8a [53.6.7], CD16/32-Biotin [24G2], CD19 [ID3], CD34 [RAM34], CD45.1 [A20.1], CD45.2 [S405-015-2], F4/80 [BM8], Flt-3 [A2F10], Gr-1 [RB6-8C5], IL-7Ra [A7R34], Mac-1 [M1/70], Sca-1 [D7], and TER119 [Ly76]. Streptavidin-PE-Cy7 and Streptavidin-PerCP-Cy5.5 were purchased from eBiosciences. An FcyR-blocking step was performed prior to staining using 1 mg/mL rat γ-globulin (Jackson ImmunoResearch). For cell cycle analysis, cells were fixed and permeabilized using Cytofix/Cytoperm (BD Pharmingen) and then stained with 10 µg/mL DAPI and, on occasion, anti-Ki67-PE-Cy7 (BD Biosciences, clone 56). Data were acquired on a LSR Fortessa (BD Pharmingen) or LSR II W (BD Pharmingen) flow cytometer and analyzed using FlowJo software [version 9.4.3, Tree Star]. Flow cytometric cell sorting was performed using an Aria (BD Pharmingen) device.

Genomic PCR

The efficiency of inducible Hhex deletion was verified by extraction of genomic DNA from fractionated samples lysed in DirectPCR (Viagen Biotech) containing proteinase K (Sigma) overnight at 55°C and subsequent PCR analysis using the 5′-CCTCTGCACAAAAAGGAAAG-3′ and 5′-ATTTAGCTCGCCGATTCTCGA-3′ and 18S (5′-GTAA CCCTGTAACCCCATTT-3′ and 5′-CCATCCAATCGG TAGTACGC-3′) at 200 µM. Amplification was performed in a LightCycler 480 real-time PCR system (Roche) using standard curves obtained from FDC-P1 cell line cDNA as a reference, and expression values were normalized to 18S.

Cell culture

MLL-ENL Hhex+/fl and MLL-ENL Hhex−/fl leukemia cells were harvested from leukemic recipient mice and cultured in growth medium [IMDM supplemented with 10% FCS with 10 ng/mL mIL-3]. Recombination mediated by CreERt2 was induced by adding 10−9 M 4-hydroxytamoxifen to the growth medium. After 7 d, cells were harvested for flow cytometric analysis or centrifuged onto a microscope slide and stained with May-Grünwald-Giemsa stain. For viable cell counts, cells were mixed with Accucheck beads [Invitrogen], stained with 1 µg/mL propidium iodide [Sigma], and enumerated by flow cytometry.

HHEX expression in human AML

Expression data and clinical annotations from human AML samples were obtained from Verhaak et al. [2009] and downloaded from Gene Expression Omnibus [GEO, GSE6891]. Classification of these samples into prognostic groups following the recommendation of the ELN was obtained from Li et al. [2013]. The raw expression files were preprocessed, including background subtractions, quantile normalization, and log2 transformation using Partek Genomics suite [version 6.6]. HHEX expression levels were compared between patients of different cytogenetics and with different risk profiles [ELN] using the Mann-Whitney U-test in Graphpad Prism [version 6.05]. Patients with high/low HHEX expression levels were identified using an unsupervised k-means clustering approach in Matlab [version R2014b], and their overall survival was compared and visualized using Kaplan-Meier statistics [log rank test] in Graphpad Prism [version 6.05].

CRISPR–CAS9 gene disruption

The first 250 coding nucleotides of mouse p15Ink4b, p16Ink4a, p19ARF, and p53 and firefly luciferase were used for optimized CRISPR design [http://www.crispr.mit.edu] of guide sequences [Supplemental Table S5]. Where possible, guide sequences that target the first exon of each gene [shared exon 2 of Cdkn2a was targeted for disruption of both p16Ink4a and p19ARF] were selected with limited probability of off target effects [quality score >50]. To generate the BsmBI-adapted ends and the 5′ PAM [NGG] site, the sequence CACCG was added to the 5′ end of the forward oligonucleotide, the sequence ACCC was added to the 5′ end, and a single C was added.
Hhex is required for acute myeloid leukemia

to the 3’ end of the reverse oligonucleotide. Forward and reverse oligonucleotide pairs for each target were annealed and ligated with BsmBI-restricted leniCRISPR (Shalem et al. 2014) and confirmed by Sanger sequencing. Ecotropic lentiviruses bearing CRISPR guides were produced in 293T cells and used to transduce MLL-ENL Hhex+/fi and MLL-ENL Hhex−/− cell lines. Virally transduced cells were selected for by the addition of 1 µg/mL puromycin (Sigma).

Western blotting

Protein samples were prepared from washed cell pellets, lysed in RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS in 10 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM PMSF, 2 mM sodium vanadate, 50 mM sodium fluoride, protease inhibitor cocktail [Roche Applied Bioscience]), and diluted in reducing Laemmli buffer or lysed directly in 4× Laemmli buffer. Proteins were resolved on precast 4–20% bis-acrylamide gels [Bio-Rad], transferred to PVDF, and immunoblotted with rabbit anti-p16 [M-15; Santa Cruz Biotechnology], rat anti-p19 (p19ARF exon 2; Rockland), rabbit anti-H3K27me3 (Millipore, 07-449), rabbit anti-H3K4me3 (Millipore, 05-928), rabbit anti-Hhex, and mouse anti-HSP70 (N6; Walter and Eliza Hall Institute).

ChIP

H3K27me3, H3K4me3, and M2-Flag ChIP was performed using a protocol based on Nelson et al. (2006) with some modifications. Briefly, cells were fixed in 1.42% paraformaldehyde and lysed in immunoprecipitation buffer (1% Triton X-100, 0.5% NP40 in 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 5 mM EDTA, protease inhibitor cocktail), and the chromatin pellet was harvested by centrifugation. DNA was fragmented in a Covaris Sonicator for 30 min at 4°C, and then protein–DNA complexes were immunoprecipitated from clarified chromat fractions using 2 µg of H3K27me3 (Millipore, 07-449) or 2 µg of H3K4me3 (Millipore, 07-473) antibodies and 30 µL of protein A-sepharose. For Hhex-Flag ChIP, 30 µL of anti-Flag (M2)-agarose beads (Sigma) was added directly to clarified chromatin fractions. Following reversal of cross-links and RNase I and proteinase K treatments, extracted DNA was purified using the QIAquick purification kit (Qiagen).

RNA sequencing

For RNA sequencing, see the Supplemental Material.

ChIP sequencing

For ChIP sequencing, see the Supplemental Material.

Coimmunoprecipitation

Whole-cell lysates were prepared by resuspending cell pellets in hypotonic buffer [20 mM Tris-HCl at pH 7.5, 10 mM KCl, 3 mM MgCl2, 1 mM PMSF, protease inhibitor cocktail] followed by 20 strokes of a dounce homogenizer. Supernatants were harvested by centrifugation, and nuclear extracts were collected in nuclear extraction buffer [20 mM Tris-HCl at pH 7.5, 300 mM NaCl, 0.5% NP40]. Next, 30 µL of anti-Flag (M2)-agarose beads was incubated with pooled fractions for 2 h at 4°C, and beads were washed extensively and resuspended in 2× reducing Laemmlioning buffer. Input (In.) and immunoprecipitation samples were subjected to SDS-PAGE and immunoblotting with the indicated antibodies.

Acknowledgments

We thank Ian Majewski for reagents and helpful comments on the manuscript, Jason Corbin and Jasmin McManus for blood analysis, Warumi Abeysekera for aligning ChIP sequencing reads, Sandra Mißud, Latina DiRago, Chayanica Nasa, William Stanley, and Stephen Wilcox for technical assistance; Walter and Eliza Hall Institute Bioservices for mouse husbandry, and the Walter and Eliza Hall Institute Flow Cytometry Facility. We also thank Tobias Herold (Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians-Universität, Munich, Germany) and Peter J.M. Valk (Department of Hematology and Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands) for providing clinical data. This work was supported by a Program grant (101664 to W.S.A.), Project grants [628386 and 1003391 to M.P.M.], a fellowship (1058344 to W.S.A.), the Independent Research Institutes Infrastructure Support (IRIIS) Scheme from the Australian Government’s National Health and Medical Research Council (NHMRC), grants-in-aid from the Cancer Council of Victoria and the Leukemia Foundation of Australia [M.P.M. and S.P.G.], a Future Fellowship from the Australian Research Council [M.P.M.], the Australia Cancer Research Fund [W.S.A.], and a Victorian State Government Operational Infrastructure Support (OIS) Grant.

References


Hhex is required for acute myeloid leukemia


Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a

Benjamin J. Shields, Jacob T. Jackson, Donald Metcalf, et al.

Genes Dev. 2016 30: 78-91
Access the most recent version at doi:10.1101/gad.268425.115

Supplemental Material
http://genesdev.cshlp.org/content/suppl/2016/01/04/30.1.78.DC1.html

References
This article cites 60 articles, 36 of which can be accessed free at:
http://genesdev.cshlp.org/content/30/1/78.full.html#ref-list-1

Creative Commons License
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.